Yasin Yilmaz1, Rana Berru Durmuş1, Başak Saraçoğlu1, Sezgin Şahin2, Amra Adrovic2, Kenan Barut2, Sevda Özel Yildiz3, Özgür Kasapçopur2, Rukiye Eker Ömeroğlu4. 1. Department of Pediatrics, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey. 2. Department of Pediatrics, Division of Pediatric Rheumatology, Istanbul University Cerrahpasa Faculty of Medicine, Istanbul, Turkey. 3. Department of Biostatistics, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey. 4. Department of Pediatrics, Division of Pediatric Rheumatology, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey.
Abstract
OBJECTIVES: This study aims to evaluate the levels of serum endocan in children with juvenile idiopathic arthritis (JIA). PATIENTS AND METHODS: Sixty-seven children with JIA (30 males, 37 females; mean age 10.4±4.9 years; range 2 to 18 years) and a sex- and age- matched healthy control group of 39 children (16 males, 23 females; mean age 9.3±4.1 years; range 1 to 17 years) were recruited. Patients with JIA were divided into two groups as the clinically active JIA group (n=27) and inactive JIA group (n=40). RESULTS: The median serum endocan level in patients with JIA was significantly higher than in the control group (633.75 ng/L vs. 379.76 ng/L, p<0.01). Comparison between patients with active JIA and inactive JIA was not significant in terms of endocan levels (618.70 ng/L vs. 687.36 ng/L, p=0.34). There was a weak negative correlation between Childhood Health Assessment Questionnaire scores of patients with JIA and serum endocan levels. CONCLUSION: The high level of serum endocan highlighted the endothelial damage in patients with JIA.
OBJECTIVES: This study aims to evaluate the levels of serum endocan in children with juvenile idiopathic arthritis (JIA). PATIENTS AND METHODS: Sixty-seven children with JIA (30 males, 37 females; mean age 10.4±4.9 years; range 2 to 18 years) and a sex- and age- matched healthy control group of 39 children (16 males, 23 females; mean age 9.3±4.1 years; range 1 to 17 years) were recruited. Patients with JIA were divided into two groups as the clinically active JIA group (n=27) and inactive JIA group (n=40). RESULTS: The median serum endocan level in patients with JIA was significantly higher than in the control group (633.75 ng/L vs. 379.76 ng/L, p<0.01). Comparison between patients with active JIA and inactive JIA was not significant in terms of endocan levels (618.70 ng/L vs. 687.36 ng/L, p=0.34). There was a weak negative correlation between Childhood Health Assessment Questionnaire scores of patients with JIA and serum endocan levels. CONCLUSION: The high level of serum endocan highlighted the endothelial damage in patients with JIA.
Authors: I Balta; S Balta; S Demirkol; D P Mikhailidis; T Celik; M Akhan; O Kurt; Y G Kurt; I Aydin; S Kilic Journal: Br J Dermatol Date: 2013-11 Impact factor: 9.302
Authors: Paul Bălănescu; Anca Lădaru; Eugenia Bălănescu; Theodor Voiosu; Cristian Băicuş; Gheorghe Andrei Dan Journal: J Clin Lab Anal Date: 2015-09-01 Impact factor: 2.352
Authors: Theodor Voiosu; Paul Bălănescu; Andreea Benguş; Andrei Voiosu; Cristian Răsvan Baicuş; Maria Barbu; Anca Ladaru; Cornelia Nitipir; Bogdan Mateescu; Mircea Diculescu; Radu Voiosu Journal: Clin Lab Date: 2014 Impact factor: 1.138
Authors: Barbara Głowińska-Olszewska; Artur Bossowski; Elżbieta Dobreńko; Andrzej Hryniewicz; Jerzy Konstantynowicz; Robert Milewski; Włodzimierz Łuczyński; Janina Piotrowska-Jastrzębska; Otylia Kowal-Bielecka Journal: Mediators Inflamm Date: 2013-03-11 Impact factor: 4.711